Larry Fong
About Larry Fong
Larry Fong Title and Role
Larry Fong is an Advisory Board Member and the Efim Guzik Distinguished Professor in Cancer Biology at the University of California, San Francisco (UCSF). He leads the Cancer Immunotherapy Program at UCSF and co-directs the Parker Institute of Cancer Immunotherapy at UCSF. Additionally, he co-leads the Cancer Immunity and Immunotherapy Program at the UCSF Cancer Center. Beyond these roles, he directs a translational research program and an NIH-funded research lab focused on cancer immunotherapy.
Larry Fong Education and Training
Larry Fong obtained his BA from Columbia University and his MD from Stanford University. He completed his internal medicine training at the University of Washington and completed his oncology fellowship and post-doctoral training at Stanford in 2002. He began as an assistant professor at UCSF and is now a distinguished professor. Fong is also an elected member of Alpha Omega Alpha and the American Society for Clinical Investigation.
Larry Fong Research Focus and Achievements
Larry Fong has focused on cancer immunotherapy for over 20 years. His research examines mechanisms underlying clinical response and resistance to immunotherapies. He has been involved in pre-clinical and clinical studies of FDA-approved immunotherapies such as sipuleucel-T and immune checkpoint inhibitors. He has also been a key figure in multiple first-in-human clinical trials for treatments like dendritic cell vaccines and ipilimumab. Fong's contributions to translational research have earned him multiple awards, including the NIH Outstanding Investigator Award.
Larry Fong Publications and Editorial Roles
Larry Fong has authored over 100 publications in high-impact journals such as the New England Journal of Medicine (NEJM), Nature, Nature Medicine, Cell, Immunity, and Cancer Discovery. He has also served on multiple journal editorial boards, including the Journal of Clinical Oncology, Journal of Immunotherapy of Cancer, and Cancer Immunology Research. His extensive publication record underscores his influence and expertise in cancer immunotherapy.
Larry Fong Industry Collaboration and Advisory Roles
Larry Fong maintains ongoing research collaborations with companies like Abbvie, Amgen, Bavarian Nordic, Bristol Myer Squibb, Dendreon, Janssen, Merck, and Roche/Genentech. He sits on the steering committee of the Roche/Genentech imCORE network. Fong has served on numerous scientific advisory boards, including Alector, Atreca, Bioatla, Bolt, Ideaya, Innovent, Nutcracker, RAPT, Senti, Soteria, TeneoBio, and Xyphos. His industry involvement highlights his standing as a leading expert in cancer immunotherapy.
Larry Fong Company Founding
Larry Fong has co-founded several companies, including FWB LLC (acquired by Streamlogic), Techbargains.com LLC (acquired by Exponential), and Keyhole Therapeutics. These ventures demonstrate his entrepreneurial spirit and his commitment to advancing technological innovations in the field of cancer research.